Skip to content

Megadyne Ace Incision/Dissection Study

Megadyne ACE Incision/Dissection Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01175889
Acronym
ACE
Enrollment
52
Registered
2010-08-05
Start date
2010-08-31
Completion date
2012-12-31
Last updated
2012-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominoplasty, Bilateral Brachioplasty, Bilateral Breast Lift, Bilateral Breast Reduction, Bilateral Lateral Thigh and Buttocks Lift

Brief summary

The Megadyne Ace™ Incision/ Dissection study is a post market, prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.

Interventions

DEVICEE-Z Clean ACE Blade

The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.

Sponsors

Megadyne Medical Products Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subject is \>18 years of age or \< 60 years old * Subject is undergoing abdominoplasty, bilateral breast reduction, bilateral breast lift, bilateral brachioplasty, bilateral lateral thigh and buttocks lift, or any combination thereof * Subject is able to discontinue anticoagulant therapy (including Aspirin) * Subject is willing and able to comply with study follow-up procedures * Subject is willing to provide written informed consent for their participation in the study

Exclusion criteria

* Subject has a history of smoking in the last 6 months prior to surgery. * Subject has a history of type I or type II Diabetes. * Subject has an active infection of any kind at the time of enrollment * Subject has a known coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Evaluate Wound Healing/Scar Formation120 DaysPrimary Effectiveness Objective Evaluate wound healing/ scar formation between incisions made using a cold steel scalpel and incisions made using the ACE Blade per photographic evidence at 120 days by an independent observer

Secondary

MeasureTime frameDescription
Evaluate patient satisfaction relating to wound healing120 DaysSecondary Effectiveness Objective Evaluate patient satisfaction relating to wound healing/ scar formation between incisions made using a cold steel scalpel and incisions made using the ACE Blade at 120 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026